Company intelligence / Profile preview

Collibri

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Collibri Therapeutics was a biotechnology company focused on the development of small molecule therapeutics for neurodegenerative and metabolic diseases. Founded by researchers from the University of California, San Francisco (UCSF), the company leveraged insights into circadian rhythms and sleep-wake cycles to identify novel drug targets. Its research aimed to address conditions where biological clock dysfunction plays a critical role in disease progression. While the company was active in the late 2010s, it appears to have ceased operations or transitioned into other research initiatives.

Therapeutic areas: NeurologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Collibri.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Collibri.

Explore the full profile